Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021
07 juin 2021 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
14 mai 2021 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021
14 mai 2021 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific Time
11 mai 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021
30 avr. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, April 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway
08 avr. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update
31 mars 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market
22 mars 2021 08h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop...
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
11 mars 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
25 févr. 2021 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...